 Ocular hypertension OHT is defined as an IOP above 21mmHg in one or both eyes without detectable glaucomatous damage. Primary open-angle glaucoma POAG is a chronic and progressive optic neuropathy of unknown etiology characterized by disc cupping, and often associated with visual field defects and elevated IOP. This disease is one of the leading causes of blindness worldwide.12 Approximately 18 to 36 of the general population are corticosteroid responders. This response is increased to 46 to 92 in patients with POAG.13 Asthma is the most common chronic respiratory illness in Canada, affecting approximately 10 of the population. For the majority of these patients, long-term inhaled corticosteroids ICS are standard of care to prevent acute asthma exacerbations.14 Although the systemic absorption of inhaled and nasal steroids has been established, the clinically relevant ocular side effects are poorly defined. 15,16 A large prospective study in 1995 by Samiy et al reported no statistically significant increase of IOP in 187 patients without glaucoma taking inhaled steroids for various pulmonary conditions.17 However, six cases of increased IOP associated with combined nasal and inhaled steroid use in non-glaucomatous patients have been reported. 18-20 A large case-control study in 1997 suggested that current users of high doses of ICS prescribed regularly for 3 or more months were at increased risk of OHT or OAG OR 1.44; 95 CI 1.01-2.06.21 In contrast, Gozalez et al. conducted a nested case-control study in 2010 with Quebec data which showed current and continuous use of ICS did not result in increased risk of glaucoma or raised IOP requiring treatment.22 Similarly, Duh et al. reported no association between inhaled budesonide daily therapy and increased IOP in 1255 asthmatic patients.23 Further, a prospective population-based cohort study published in 2012 suggested no association between the development of OAG and ICS in the elderly.24 In 2013, our group published a randomized double-masked controlled trial that showed no evidence of IOP elevation after 6 weeks use of beclomethasone nasal spray in 19 patients with OHT and POAG.25 The purpose of the current study protocol would be to extend the study to investigate ICS in the same patient population. 